# US 2024/0002815 A1 · Compositions and methods for treating ornithine transcarbamylase deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002815 A1
- Document ID: US20240002815A1
- Status: Published application
- Kind: A1
- Application number: 18/319,977
- Filed: 2023-05-18
- Published: 2024-01-04
- Earliest claimed: 2018-12-06
- Assignees: Arcturus Therapeutics, Inc.
- Applicants: Arcturus Therapeutics, Inc.
- Inventors: Carlos G. PEREZ-GARCIA; Kiyoshi TACHIKAWA; Daiki MATSUDA; Padmanabh CHIVUKULA
- Web page: https://patentgrep.com/patent/US20240002815A1

## CPC

- C12N 9/1018: {Carboxy- and carbamoyl transferases (2.1.3)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12Y 201/03003: Ornithine carbamoyltransferase (2.1.3.3)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by Arabidopsis thaliana for use in treating OTC deficiency in a patient.

## Claims

### Claim 1

A polynucleotide encoding an ornithine transcarbamylase (OTC) protein comprising the amino acid sequence of SEQ ID NO:4 and having OTC enzymatic activity, wherein
(i) the polynucleotide comprises a sequence of SEQ ID NO:221; or
(ii) the polynucleotide comprises a sequence of SEQ ID NO:221, wherein T is substituted with U.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA comprising a 3′poly A tail.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA comprising a 5′ untranslated region (5′UTR).

### Claim 10 (depends on 9)

The polynucleotide of claim 9, wherein the 5′UTR is derived from a gene expressed by Arabidopsis thaliana.

### Claim 11 (depends on 10)

The polynucleotide of claim 10, wherein the 5′ UTR comprises a sequence selected from SEQ ID NO: 6, SEQ ID NOS: 125-127, and SEQ ID NOS: 230-250.

### Claim 12 (depends on 11)

The polynucleotide of claim 11, wherein the 5′UTR comprises a sequence of SEQ ID NO: 6.

### Claim 13 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA comprising a 3′ UTR.

### Claim 14 (depends on 13)

The polynucleotide of claim 13, wherein the 3′ UTR comprises a sequence selected from SEQ ID NOS: 16-22.

### Claim 15 (depends on 1)

The polynucleotide of claim 1, comprising a Kozak sequence of SEQ ID NO: 23 or a partial Kozak sequence of SEQ ID NO: 24.

### Claim 16 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA comprising a 5′ cap.

### Claim 17 (depends on 16)

The polynucleotide of claim 16, wherein the 5′ cap is m7GpppGm having the following structure:

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA comprising
(a) a sequence of SEQ ID NO: 21; or
(b) a sequence of SEQ ID NO: 6 and a sequence of SEQ ID NO: 21.

### Claim 20 (depends on 1)

The polynucleotide of claim 1, wherein the polynucleotide is an mRNA, and wherein
(a) the percentage of uracil nucleobases in the coding region of the polynucleotide is reduced with respect to the percentage of uracil nucleobases in the wild-type OTC nucleic acid sequence; or
(b) 1-100% of the uridines are modified uridine analogs; or
(c) 1-100% of the uridine nucleotides are each independently a modified uridine analog selected from the group consisting of 5-methoxyuridine, N1-methylpseudouridine, 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-carboxymethylesteruridine, 5-formyluridine, 5-propynyluridine, 5-bromouridine, 5-fluorouridine, 5-iodouridine, 2-thiouridine, 6-methyluridine, N1-ethylpseudouridine, N1-propylpseudouridine, N1-cyclopropylpseudouridine, N1-phenylpseudouridine, N1-aminomethylpseudouridine, N3-methylpseudouridine, N1-hydroxypseudouridine, N1-hydroxymethylpseudouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methylaminomethyl-2-thiouridine, 5-carbamoylmethyluridine, 5-carbamoylmethyl-2′-O-methyluridine, 1-methyl-3-(3-amino-3-carboxypropy)pseudouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethyluridine, 5-methyldihydrouridine, 5-taurinomethyluridine, 5-taurinomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 2′-O-methylpseudouridine, 2-thio-2′O-methyluridine, and 3,2′-O-dimethyluridine; or
(d) 100% of the uridine nucleotides are 5-methoxyuridine; or
(e) 100% of the uridine nucleotides are N1-methylpseudouridine.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 1)

A pharmaceutical composition comprising the polynucleotide of claim 1 and pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a lipid formulation.

### Claim 29 (depends on 20)

A pharmaceutical composition comprising the polynucleotide of claim 20 and pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a lipid formulation.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 29)

A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient a pharmaceutical composition of claim 29, wherein upon administration of the pharmaceutical composition to the patient, the protein of SEQ ID NO: 4 is expressed in the patient.

### Claim 37 (depends on 1)

A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient a polynucleotide of claim 1, wherein the polynucleotide expresses the protein of SEQ ID NO: 4 in the patient.

### Claim 38 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 39

(canceled)

### Claim 40

An mRNA encoding an OTC protein having the amino acid sequence of SEQ ID NO: 4, wherein the mRNA comprises a polynucleotide sequence of SEQ ID NO:221, wherein T is substituted with U, and wherein the encoded protein has OTC enzymatic activity.

### Claim 41 (depends on 40)

The mRNA of claim 40, wherein
(a) 1-100% of the uridines are modified uridine analogs; or
(b) 1-100% of the uridine nucleotides are each independently a modified uridine analog selected from the group consisting of 5-methoxyuridine, N1-methylpseudouridine, 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-carboxymethylesteruridine, 5-formyluridine, 5-propynyluridine, 5-bromouridine, 5-fluorouridine, 5-iodouridine, 2-thiouridine, 6-methyluridine, N1-ethylpseudouridine, N1-propylpseudouridine, N1-cyclopropylpseudouridine, N1-phenylpseudouridine, N1-aminomethylpseudouridine, N3-methylpseudouridine, N1-hydroxypseudouridine, N1-hydroxymethylpseudouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methylaminomethyl-2-thiouridine, 5-carbamoylmethyluridine, 5-carbamoylmethyl-2′-O-methyluridine, 1-methyl-3-(3-amino-3-carboxypropy)pseudouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethyluridine, 5-methyldihydrouridine, 5-taurinomethyluridine, 5-taurinomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 2′-O-methylpseudouridine, 2-thio-2′O-methyluridine, and 3,2′-O-dimethyluridine; or
(c) 100% of the uridine nucleotides are 5-methoxyuridine; or
(d) 100% of the uridine nucleotides are N1-methylpseudouridine.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)
